AZD5069 is a potent, selective, and orally bioavailable small-molecule antagonist of the CXC chemokine receptor 2 (CXCR2). It is a bicyclic amidine derivative with the chemical formula C₂₀H₂₃N₅O₂S and a molecular weight of 397.49 g/mol. The compound was developed by AstraZeneca as a potential therapeutic agent. Its primary application is in the treatment of inflammatory respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and bronchiectasis. By blocking the CXCR2 receptor, AZD5069 inhibits the recruitment and activation of neutrophils to the lungs, thereby targeting a key driver of neutrophilic inflammation. It has been investigated in multiple clinical trials for these indications. While primarily developed for respiratory conditions, its mechanism of action targeting CXCR2-mediated inflammation also positions it as a candidate for other diseases involving neutrophilic inflammation. The development status of AZD5069 has advanced through Phase II clinical studies.